Table 2.

Randomized trials evaluating neoadjuvant trastuzumab (H) and lapatinib (L) with chemotherapy in HER2+ breast cancer.

Study	Treatment arm	N	pCR (%)	p-value
NSABP B-4129	H	181	49.4
	L	174	47.4	0.78
	H + L	174	60.2	0.056
NeoALTTO30	H	149	29.5
	L	154	24.7	0.34
	H + L	152	51.3	0.0001
CALGB 4060131	H	120	46
	L	67	32
	H + L	118	56	0.13
TRIO-US B0732	H	34	47
	L	36	25	0.14
	H + L	58	52	0.45
EORTC 1005433	H	53	52
	L	23	36
	H + L	52	56
CHER-LOB34	H	36	25.0
	L	39	26.3
	H + L	46	46.7	0.019
Holmes and colleagues35	H	26	54
	L	29	45
	H + L	23	74

HER2, human epidermal growth factor 2; HER2+, HER2-overexpressing; L, lapatinib; pCR, pathologic complete response; H, trastuzumab.